DOES METHYLPHENIDATE ENHANCE COGNITION IN NORMAL RATS AND DOES IT AFFECT NEURONAL POPULATION?
Keywords:
Attention deficit hyper activity disorder, Cognitive function, Learning, Memory, Methylphenidate, HippocampusAbstract
Objective: Methylphenidate [MPH] is one of the drugs of choice for children with Attention Deficit Hyperactivity Disorder [ADHD] since many decades with good effect. Consumption of this drug by normal children and adolescents to boost their cognition skills is of concern. MPH induced cognitive enhancement involves brain dopamine and norepinephrine levels in areas concerned with cognition especially hippocampus. Altered expression of these neurotransmitters can affect neuronal population of hippocampus which may have the significant effect in later part of the life. Hence we evaluate the effect of MPH on cognition and histopathological changes in the hippocampus and dentate gyrus.
Methods: Two month old male wistar rats were given either 2 or 5 mg/kg dose of MPH for 10 successive days and another set of rats served as control. The rats were tested for learning and memory activities followed by histopathological studies in hippocampus and dentate gyrus using Nissl staining.
Results: MPH at both the doses has enhanced learning abilities as well as retention of memory. The histopathological studies did not show any significant effect on dentate gyrus as well as hippocampus.
Conclusion: Though MPH is known to provide sound results in ADHD, from the present study it is clear that MPH treatment in normal rats also temporarily enhance the cognitive skills especially declarative memory. However, its effect on long term memory is to be investigated. MPH treatment has not affected the neuronal population hence possible cytotoxic effects on neurons can be ruled out from the present study.
Â
Downloads
References
Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: a community perspective. J Am Academy Child Adolescent Psychiatry 2000;39:975-84.
Morris K. Experts urge smart thinking on cognitive enhancers. Lancet Neurol 2008;7:476-7.
Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008;456:702-5.
Del Campo N, Chamberlain SR, Sahakain BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011;69:145-57.
Advokat C, Lane SM, Luo C. College students with and without ADHD: Comparison of self report of medication usage, study habits and academic achievement. J Attention Disorders 2011;15:656-66.
Camp Bruno JA, Herting RL. Cognitive effects of milacemide and methylphenidate in healthy young adults. Psychopharmacology (Berl) 1994;115:46-52.
Mehta. MA, Calloway P, Sahakian BJ. Amelioration of specific working memory deficits by methylphenidate in a case of adult attention deficit/hyperactivity disorder. J Psychopharmacol 2000;14:299-302.
Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006;60:1111-20.
Kuczenski R, Segal DS. Exposure of adolescent rats to oralmethylphenidate: preferential effects on extracellular norepinephrine and absence of sensitisation and cross-sensitisation to methamphetamine. J Neurosci 2002;22:7264-71.
Gamo NJ, Wang M, Arnsten AF. Methylphenidate and Atomoxetine enhance prefrontal function through alpha 2-adrenergic and dopamine D1 receptor. J Am Academy Child Adolescent Psychiatry 2010;49:1011-23.
Sampath Madhyastha, Somayaji SN, Rao MS, Nalini K, Bairy KL. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol 2002;80:1076-84.
Gu Y, Janoshcka S, Ge S. Neurogenesis and hippocampal plasticity in adult brain. Curr Top Behav Neurosci 2013;15:31-48.
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ. "Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration". Pharmacotherapy 2006;26:1501-10.
Ross RG, Harris JG, Olincy A, Radant A. Eye movement task measures inhibition and spatial working memory in adults with schizophrenia, ADHD, and a normal comparison group. Psychiatry Res 2000;95:35–42.
Cooper NJ, Keage H, Hermens D, Williams LM, Debrota D, Clark CR, et al. The dose-dependent effect of methylphenidate on performance, cognition and psychophysiology. J Integrative Neurosci 2005;4:123–44.
Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacol 2005;178:286–95.
Kordon A, Kahl KG, Wahl K. A new understanding of attention-deficit disorders—beyond the age-at-onset criterion of DSM-IV. European Archives of Psychiatry and Clinical Neuroscience 2006;256(Suppl 1):i47-54.
Unrug A, Coenen A, Luijtelaar G. Effects of the tranquillizer diazepam and the stimulant methylphenidate on alertness and memory. Neuropsychobiology 1997;36:42–8.
Riordan HJ, Flashman LA, Saykin AJ, Frutiger SA, Carroll KE, Huey L. Neuropsychological correlates of methylphenidate treatment in adults ADHD with and without depression. Arch Clin Neuropsychol 1999;14:217–33.
Schermer M, Bolt I, de Jongh R. The future of psychopharmacological enhancements: expectations and policies. Neuroethics 2009;2:75-87.
Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005;57:1377–84.
Sadasivan Shankar, Brooks B Pond, Amar K Pani, Chunxu Qu, Yun Jiao, Richard J Smeyne. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. Plos One 2012;7:1-9.
BartlJasmin, Takatoshi Mori, Peter Riederer, Hiroki Ozawa, Edna Grunblatt. Methylphenidate enhances neural stem cell differentiation. J Orthomol Psychiatry 2013;1:5.